These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21531054)

  • 1. Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position.
    Nguyen T; Sakasegawa Y; Doh-Ura K; Go ML
    Eur J Med Chem; 2011 Jul; 46(7):2917-29. PubMed ID: 21531054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiprion activity of functionalized 9-aminoacridines related to quinacrine.
    Nguyen TH; Lee CY; Teruya K; Ong WY; Doh-ura K; Go ML
    Bioorg Med Chem; 2008 Jul; 16(14):6737-46. PubMed ID: 18556207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein.
    Vogtherr M; Grimme S; Elshorst B; Jacobs DM; Fiebig K; Griesinger C; Zahn R
    J Med Chem; 2003 Aug; 46(17):3563-4. PubMed ID: 12904059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prion inhibition with multivalent PrPSc binding compounds.
    Mays CE; Joy S; Li L; Yu L; Genovesi S; West FG; Westaway D
    Biomaterials; 2012 Oct; 33(28):6808-22. PubMed ID: 22748770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.
    Villa V; Tonelli M; Thellung S; Corsaro A; Tasso B; Novelli F; Canu C; Pino A; Chiovitti K; Paludi D; Russo C; Sparatore A; Aceto A; Boido V; Sparatore F; Florio T
    Neurotox Res; 2011 May; 19(4):556-74. PubMed ID: 20405353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivity of 9-aminoacridine drug quinacrine with glutathione limits its antiprion activity.
    Šafařík M; Moško T; Zawada Z; Šafaříková E; Dračínský M; Holada K; Šebestík J
    Chem Biol Drug Des; 2017 Jun; 89(6):932-942. PubMed ID: 27933730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations.
    Dollinger S; Löber S; Klingenstein R; Korth C; Gmeiner P
    J Med Chem; 2006 Nov; 49(22):6591-5. PubMed ID: 17064077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinacrine reactivity with prion proteins and prion-derived peptides.
    Zawada Z; Šafařík M; Dvořáková E; Janoušková O; Březinová A; Stibor I; Holada K; Bouř P; Hlaváček J; Sebestík J
    Amino Acids; 2013 May; 44(5):1279-92. PubMed ID: 23340659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous quinacrine treatment results in the formation of drug-resistant prions.
    Ghaemmaghami S; Ahn M; Lessard P; Giles K; Legname G; DeArmond SJ; Prusiner SB
    PLoS Pathog; 2009 Nov; 5(11):e1000673. PubMed ID: 19956709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chelating compound, chrysoidine, is more effective in both antiprion activity and brain endothelial permeability than quinacrine.
    Doh-ura K; Tamura K; Karube Y; Naito M; Tsuruo T; Kataoka Y
    Cell Mol Neurobiol; 2007 May; 27(3):303-16. PubMed ID: 17235694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments.
    Klingenstein R; Löber S; Kujala P; Godsave S; Leliveld SR; Gmeiner P; Peters PJ; Korth C
    J Neurochem; 2006 Aug; 98(3):748-59. PubMed ID: 16749906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
    Korth C; May BC; Cohen FE; Prusiner SB
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9836-41. PubMed ID: 11504948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils.
    Bocharova OV; Breydo L; Salnikov VV; Baskakov IV
    Biochemistry; 2005 May; 44(18):6776-87. PubMed ID: 15865423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acridin-9-yl exchange: a proposal for the action of some 9-aminoacridine drugs.
    Sebestík J; Safarík M; Stibor I; Hlavácek J
    Biopolymers; 2006; 84(6):605-14. PubMed ID: 16933221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutics for prion diseases].
    Doh-ura K
    Rinsho Shinkeigaku; 2003 Nov; 43(11):820-2. PubMed ID: 15152474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies.
    Alexandrenne C; Hanoux V; Dkhissi F; Boquet D; Couraud JY; Wijkhuisen A
    J Neuroimmunol; 2009 Apr; 209(1-2):50-6. PubMed ID: 19232746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier.
    Dohgu S; Yamauchi A; Takata F; Sawada Y; Higuchi S; Naito M; Tsuruo T; Shirabe S; Niwa M; Katamine S; Kataoka Y
    Cell Mol Neurobiol; 2004 Apr; 24(2):205-17. PubMed ID: 15176436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of anti-prion agents to glycosaminoglycans: evidence from electronic absorption and circular dichroism spectroscopy.
    Zsila F; Gedeon G
    Biochem Biophys Res Commun; 2006 Aug; 346(4):1267-74. PubMed ID: 16793017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino-terminal parathyroid hormone fragment analogs containing alpha,alpha-di-alkyl amino acids at positions 1 and 3.
    Shimizu N; Dean T; Khatri A; Gardella TJ
    J Bone Miner Res; 2004 Dec; 19(12):2078-86. PubMed ID: 15537452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies.
    Murakami-Kubo I; Doh-Ura K; Ishikawa K; Kawatake S; Sasaki K; Kira J; Ohta S; Iwaki T
    J Virol; 2004 Feb; 78(3):1281-8. PubMed ID: 14722283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.